How to Buy Zymeworks Stock
Zymeworks Inc
Zymeworks is a biotech company located in British Columbia, Canada, which is part of the Healthcare sector, and is traded under the ticker ZYME on the NASDAQ exchange.
Zymeworks stock last closed at $12.25, down 2.39% from the previous day, and has increased 13.74% in one year. It has overperformed other stocks in the Biotechnology industry by 0.61 percentage points. Zymeworks stock is currently +53.7% from its 52-week low of $7.97, and -30.79% from its 52-week high of $17.70.
As of Mar 14, 2025, there are 69.58M shares of ZYME outstanding. The market value of ZYME is $852.32M. In the past 24 hours, 577,523 ZYME shares were traded.
How to Buy Zymeworks Stock
Wondering how to invest in Zymeworks stock? Here's how.
- Figure out where to buy Zymeworks stock: You need to choose an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you determine where to buy Zymeworks stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Put funds into your brokerage account: Pick your method of payment and add your information.
- Analyze Zymeworks stock: The Zymeworks ticker symbol is ZYME. Is Zymeworks stock a good investment? Should you buy shares of ZYME? How do ZYME's underlying business fundamentals look? Do top analysts think Zymeworks is a good buy? Why has ZYME's stock price moved recently? (Hint: Our stock analysis website can help you figure out if ZYME is a good stock to buy).
- Execute your ZYME buy order: Decide if you will purchase ZYME shares at the current market price or use a limit order to buy ZYME stock at a specific price.
- Get key alerts regarding your ZYME investment: Create a watchlist to get the latest news on your new investment in Zymeworks shares.
Step 1: Figure out where to buy Zymeworks stock
You will need a brokerage account in order to access the NASDAQ market and buy ZYME shares.
Our recommended brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global financial markets: From Tech to Energy, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal information so you are able to invest in ZYME stock today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to start your new brokerage account.
- Submit your information by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have finished signing up on a investment app, you can securely and quickly fund your account:
Watch the tutorial below for more details transferring funds into your investment account.
Step 4: Analyze Zymeworks stock
After you have chosen the best place to buy Zymeworks stock, it's critical to research their stock prior to investing, so you truly wrap your head around the risk and upside.
Zymeworks shares at a glance
ZYME Fundamentals
WallStreetZen was built to help average investors do more accurate fundamental analysis.
You can see all of the due diligence checks on ZYME's stock page.
Is ZYME stock undervalued or overvalued?
Investors use many financial metrics, analyses, models, and charts to gauge ZYME's fair value.
Using relative valuations ratios:
- ZYME could be undervalued based on its P/B ratio of 2.52x, relative to Biotechnology industry P/B ratio of 4.68x
You can access more valuation analysis on ZYME's stock here.
Is ZYME a healthy company?
Passed Health Checks:
- There are more short-term assets than long-term liabilities on the ZYME balance sheet.
- ZYME has a low debt to equity ratio of 0.37.
- Total ZYME debt is lower than 5 years ago, relative to shareholder equity.
- ZYME has cash burn of 112035000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the ZYME balance sheet.
- ZYME has $225.78M in cash and short term investments. This is sufficient to cover its annual cash burn of $112.04M.
Failed Health Checks:
- ZYME profit margin has gone down from -156.1% to -160.8% in the past year.
Is ZYME stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 6 Wall Street analysts who give forecasts on ZYME, the consensus analyst rating on Zymeworks is a Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
Latest ZYME Analyst Forecasts
Andrew Berens, a bottom 2% analyst from Leerink Partners upgrades ZYME to a buy rating and raises their ZYME price target from $10.00 to $25.00, on Nov 7, 2024.
Stephen Willey, a bottom 4% analyst from Stifel Nicolaus maintains ZYME with a strong buy rating and raises their ZYME price target from $21.00 to $28.00, on Oct 28, 2024.
You can dive deeper into what analysts are forecasting on the Zymeworks stock forecast page.
ZYME Technicals
ZYME Performance Metrics
Last year, ZYME revenue was $76.30M. In the last five year, ZYME's revenue has increased by 20.9% per year. This was slower than the Biotechnology industry average of 44.6%.
You can research ZYME's earnings and revenue performance here.
Who is buying/selling ZYME?
Over the past 12 months, insiders at ZYME have bought more shares than they have sold.
Ecor1 Capital LLC, Director of ZYME, was the latest ZYME insider to buy. They bought $5,847,424.66 worth of ZYME stock on Mar 13, 2025.
Learn more about who owns ZYME stock here.
Can I rely on ZYME as an income stream?
No, Zymeworks doesn't provide an income stream by paying out dividends.
What do other traders have to say about ZYME?
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Execute your ZYME buy order
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally the best for newer investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a particular dollar amount, use a limit order.
Press the Open Trade button and eToro will place the order.
If you want additional help with buying stocks on eToro, watch the helpful video below:
Step 6: Get key alerts regarding your ZYME investment
Now that you own some shares in ZYME, you'll want to stay up-to-date on your new stock purchase.
Create a watchlist to see the latest developments about your ZYME stock.
ZYME Feed
How to Buy Stock in Zymeworks
To summarize, here are the 6 steps to buy Zymeworks stock:
- Figure out where to buy Zymeworks stock
- Create a brokerage account
- Put funds into your brokerage account
- Analyze Zymeworks stock
- Execute your ZYME buy order
- Get key alerts regarding your ZYME investment
If you are looking for a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to keep tabs on your investment in Zymeworks, add ZYME to your watchlist by clicking the button below.
Other Articles You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.